Combination chemotherapy with capecitabine (C), irinotecan (I), oxaliplatin (O), and bevacizumab (B; XELOXIRIA) as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a phase I-II trial.

被引：0
|
作者：
Bazarbashi, S. [1 ]
Aljubran, A. H. [1 ]
Soudy, H. [1 ]
Darwish, A. [1 ]
Eltigani, A. [1 ]
Nabil-Ahmed, M. [1 ]
Edesa, W. [1 ]
Almubarak, M. [1 ]
Abu Sabaa, A. [1 ]
Shoukri, M. [1 ]
机构：
[1] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e14073
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14073
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the GONO group
    Burs, S.
    Masi, G.
    Loupakis, F.
    Antonuzzo, A.
    Tognarini, L.
    Sonaglio, C.
    Chiara, S.
    Pfanner, E.
    Brunetti, I
    Petrini, I
    Baldi, G.
    Barletta, M.
    Allegrini, G.
    Ricci, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2007, 18 : VII27 - VII27
  • [22] Phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer.
    Vanhoefer, UJ
    Mayer, S
    Achterrath, W
    Hense, J
    Omidi, S
    Frings, S
    Harstrick, A
    Wilke, H
    Seeber, S
    ANNALS OF ONCOLOGY, 2000, 11 : 49 - 49
  • [23] CAPECITABINE AND OXALIPLATIN (XELOX) COMBINATION CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER-A PHASE II STUDY
    Tawfik, Hesham
    El-Deen, Hanan Gamal
    ANNALS OF ONCOLOGY, 2012, 23 : 98 - 98
  • [24] Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal cancer
    Jungic, Sasa
    Tubic, Biljana
    Gajanin, Radoslav
    Gojkovic, Zdenka
    Rakita, Ivanka
    VOJNOSANITETSKI PREGLED, 2017, 74 (03) : 249 - 255
  • [25] Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
    P García-Alfonso
    A J Muñoz-Martin
    S Alvarez-Suarez
    Y Jerez-Gilarranz
    M Riesco-Martinez
    P Khosravi
    M Martin
    British Journal of Cancer, 2010, 103 : 1524 - 1528
  • [26] Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
    Garcia-Alfonso, P.
    Munoz-Martin, A. J.
    Alvarez-Suarez, S.
    Jerez-Gilarranz, Y.
    Riesco-Martinez, M.
    Khosravi, P.
    Martin, M.
    BRITISH JOURNAL OF CANCER, 2010, 103 (10) : 1524 - 1528
  • [27] Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial.
    Patt, YZ
    Liebmann, J
    Diamandidis, D
    Eckhardt, SG
    Javle, M
    Justice, GR
    Keiser, W
    Lee, FC
    Miller, W
    Lin, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 270S - 270S
  • [28] Phase I study of the IXO regimen, irinotecan (I), capecitabine (X), oxaliplatin (O), as first-line therapy for metastatic colorectal cancer: Final survival results
    Maroun, J.
    Jonker, D.
    Cripps, C.
    Goel, R.
    Asmis, T.
    Marginean, H.
    Chiritescu, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Phase II study of bevacizumab (B) plus oxaliplatin (Ox) plus capecitabine (C) followed by bevacizumab (B) plus erlotinib (E) as first-line treatment in metastatic colorectal cancer (mCRC).
    Munoz, A.
    Pericay, C.
    Llorente, B.
    Alonso, V.
    Duenas, R.
    Roca, J.
    Rivera, F.
    Falco, E.
    Alvarez, I.
    Salud, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer
    Bajetta, E.
    Celio, L.
    Ferrario, E.
    Di Bartolomeo, M.
    Denaro, A.
    Dotti, K.
    Mancin, M.
    Bajetta, R.
    Colombo, A.
    Pusceddu, S.
    ANNALS OF ONCOLOGY, 2007, 18 (11) : 1810 - 1816
12345